Flavonoids against the SARS-CoV-2 induced inflammatory storm.

Szczegóły
Abstrakt

Tytuł:: Flavonoids against the SARS-CoV-2 induced inflammatory storm.
Autorzy:: Liskova A; Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Samec M; Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Koklesova L; Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01 Martin, Slovakia.
Samuel SM; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Zhai K; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Al-Ishaq RK; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Abotaleb M; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Nosal V; Department of Neurology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Kajo K; Department of Pathology, St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia; Biomedical Research Centre, Slovak Academy of Sciences, Bratislava, Slovakia.
Ashrafizadeh M; Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Tuzla, Istanbul, Turkey; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul, Turkey.
Zarrabi A; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul, Turkey.
Brockmueller A; Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Munich, Germany.
Shakibaei M; Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Munich, Germany.
Sabaka P; Department of Infectiology and Geographical Medicine, Faculty Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
Mozos I; Department of Functional Sciences, 'Victor Babes' University of Medicine and Pharmacy, Timisoara, Romania; Center for Translational Research and Systems Medicine, 'Victor Babes' University of Medicine and Pharmacy, Timisoara, Romania.
Ullrich D; Department of Leadership, Faculty of Military Leadership, University of Defence, Brno, Czech Republic.
Prosecky R; 2nd Department of Internal Medicine, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
La Rocca G; Human Anatomy Section, Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo and Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.
Caprnda M; 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia.
Büsselberg D; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Rodrigo L; Faculty of Medicine, University of Oviedo and Central University Hospital of Asturias (HUCA), Oviedo, Spain.
Kruzliak P; 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic. Electronic address: .
Kubatka P; Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia. Electronic address: .
Źródło:: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jun; Vol. 138, pp. 111430. Date of Electronic Publication: 2021 Feb 25.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Paris : Editions Scientifiques Elsevier
Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982-
MeSH Terms:: SARS-CoV-2*
COVID-19 Drug Treatment*
Anti-Inflammatory Agents/*therapeutic use
Cytokine Release Syndrome/*drug therapy
Flavonoids/*therapeutic use
Animals ; Anti-Inflammatory Agents/pharmacology ; COVID-19/immunology ; Cytokine Release Syndrome/immunology ; Flavonoids/pharmacology ; Humans
References:: Int J Mol Sci. 2019 Feb 15;20(4):. (PMID: 30769917)
Pharmacol Res. 2020 Sep;159:105051. (PMID: 32603772)
Toxicol Appl Pharmacol. 2018 Sep 15;355:93-102. (PMID: 29960001)
Bioorg Med Chem. 2018 Oct 1;26(18):5140-5150. (PMID: 30227999)
Immunopharmacol Immunotoxicol. 2020 Apr;42(2):93-100. (PMID: 32048561)
Chem Biol Drug Des. 2019 Dec;94(6):2023-2030. (PMID: 31436895)
Nat Commun. 2020 Oct 2;11(1):4938. (PMID: 33009401)
J Nat Prod. 2020 Oct 23;83(10):2950-2959. (PMID: 32989985)
Lipids Health Dis. 2018 Apr 25;17(1):95. (PMID: 29695233)
Bioinformation. 2013 Nov 11;9(18):889-95. (PMID: 24307765)
J Biomol Struct Dyn. 2021 Jul;39(11):4089-4099. (PMID: 32567487)
Biochemistry (Mosc). 2020 Jul;85(7):833-837. (PMID: 33040727)
Oxid Med Cell Longev. 2019 Dec 13;2019:1563024. (PMID: 31915502)
Phytochem Rev. 2021;20(4):773-795. (PMID: 32982616)
Nutrients. 2020 Feb 12;12(2):. (PMID: 32059369)
Proc Nutr Soc. 2010 Aug;69(3):273-8. (PMID: 20569521)
Comb Chem High Throughput Screen. 2021;24(2):294-305. (PMID: 32767929)
Leukemia. 2020 Jul;34(7):1726-1729. (PMID: 32483300)
CNS Neurosci Ther. 2019 May;25(5):575-590. (PMID: 30676698)
Phytomedicine. 2020 Feb;67:153150. (PMID: 31958713)
Cancers (Basel). 2018 Dec 28;11(1):. (PMID: 30597838)
Phytochemistry. 2009 Jul;70(10):1255-61. (PMID: 19682714)
Arch Med Res. 2020 Oct;51(7):608-612. (PMID: 32682575)
Food Funct. 2014 Sep;5(9):2357-64. (PMID: 25088664)
Biosci Rep. 2021 Jan 29;41(1):. (PMID: 33146673)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Nat Commun. 2019 Aug 13;10(1):3651. (PMID: 31409784)
J Cardiovasc Pharmacol. 2019 Oct;74(4):326-335. (PMID: 31356553)
Nutrients. 2020 May 01;12(5):. (PMID: 32369998)
Chin Med. 2020 Sep 25;15:102. (PMID: 32994803)
Nutrients. 2018 Oct 03;10(10):. (PMID: 30282902)
Front Immunol. 2020 May 15;11:1061. (PMID: 32574262)
Evid Based Complement Alternat Med. 2020 Nov 5;2020:7493281. (PMID: 33204291)
J Diabetes. 2020 Sep;12(9):649-658. (PMID: 32394639)
Antioxidants (Basel). 2019 Feb 05;8(2):. (PMID: 30764536)
Front Pharmacol. 2018 Jan 09;8:975. (PMID: 29375379)
Molecules. 2018 Jun 06;23(6):. (PMID: 29882783)
Am J Chin Med. 2018;46(4):751-767. (PMID: 29754503)
J Microbiol. 2012 Apr;50(2):293-300. (PMID: 22538659)
Nutrients. 2013 Aug 28;5(9):3367-87. (PMID: 23989753)
Toxicol Appl Pharmacol. 2012 Jun 1;261(2):181-8. (PMID: 22521609)
BioData Min. 2020 Sep 24;13:15. (PMID: 32983259)
Trends Pharmacol Sci. 2020 Sep;41(9):598-610. (PMID: 32711925)
Nutrients. 2019 Feb 02;11(2):. (PMID: 30717392)
Biofactors. 2019 Jul;45(4):563-574. (PMID: 31131946)
Bioorg Med Chem. 2006 Dec 15;14(24):8295-306. (PMID: 17046271)
Am J Physiol Endocrinol Metab. 2020 Oct 1;319(4):E689-E708. (PMID: 32755302)
Toxicol Appl Pharmacol. 2019 Feb 15;365:19-29. (PMID: 30594691)
Pharm Biol. 2018 Dec;56(1):465-484. (PMID: 31070530)
Molecules. 2019 Jan 21;24(2):. (PMID: 30669635)
Cytokine Growth Factor Rev. 2020 Jun;53:66-70. (PMID: 32418715)
Oxid Med Cell Longev. 2018 Aug 5;2018:8987173. (PMID: 30174782)
Biomed Pharmacother. 2019 Jan;109:1978-1987. (PMID: 30551453)
Front Immunol. 2020 Jul 10;11:1708. (PMID: 32754163)
Minerva Gastroenterol (Torino). 2021 Jun;67(2):190-195. (PMID: 33016666)
Life Sci. 2020 Sep 15;257:118075. (PMID: 32653522)
Antioxidants (Basel). 2020 Mar 27;9(4):. (PMID: 32230772)
Acta Diabetol. 2020 Jul;57(7):779-783. (PMID: 32506195)
J Diabetes Complications. 2020 Dec;34(12):107723. (PMID: 32900588)
J Ethnopharmacol. 2020 Jan 30;247:112282. (PMID: 31604138)
Physiol Int. 2020 Mar;107(1):82-91. (PMID: 32491283)
Agents Actions. 1982 Jul;12(3):298-302. (PMID: 6982607)
Compr Rev Food Sci Food Saf. 2018 Sep;17(5):1054-1112. (PMID: 33350159)
Phytomedicine. 2021 May;85:153315. (PMID: 32978039)
Sci Rep. 2019 Oct 17;9(1):14906. (PMID: 31624286)
Redox Biol. 2017 Aug;12:311-324. (PMID: 28285192)
Antioxidants (Basel). 2020 Aug 13;9(8):. (PMID: 32823497)
J Biomol Struct Dyn. 2022 Jan;40(1):86-100. (PMID: 32896226)
FEBS J. 2019 May;286(9):1656-1667. (PMID: 30565859)
J Cancer Res Clin Oncol. 2020 Dec;146(12):3137-3154. (PMID: 33063131)
Mol Aspects Med. 2018 Jun;61:41-49. (PMID: 29317252)
Food Funct. 2020 Feb 26;11(2):1322-1333. (PMID: 32031202)
Int J Infect Dis. 2020 Dec;101:42-45. (PMID: 32950735)
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E830-E833. (PMID: 32310688)
iScience. 2020 Aug 21;23(8):101400. (PMID: 32738607)
Pharmacol Res. 2020 Aug;158:104939. (PMID: 32445956)
Nutrients. 2019 Sep 25;11(10):. (PMID: 31557798)
Front Physiol. 2020 Oct 06;11:574753. (PMID: 33123031)
Molecules. 2019 Nov 07;24(22):. (PMID: 31703341)
Clin Rheumatol. 2020 Jul;39(7):2085-2094. (PMID: 32474885)
In Vivo. 2016 11-12;30(6):777-785. (PMID: 27815461)
J Enzyme Inhib Med Chem. 2020 Dec;35(1):145-151. (PMID: 31724441)
Nutrients. 2016 May 19;8(5):. (PMID: 27213439)
Mem Inst Oswaldo Cruz. 2020 Sep 30;115:e200207. (PMID: 33027419)
J Agric Food Chem. 2012 Sep 12;60(36):9055-61. (PMID: 22891874)
Biochem Pharmacol. 2018 Sep;155:494-509. (PMID: 30071202)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Sci Rep. 2018 Jul 12;8(1):10523. (PMID: 30002398)
Virol J. 2019 Feb 20;16(1):21. (PMID: 30786886)
Antioxidants (Basel). 2020 Jul 24;9(8):. (PMID: 32722164)
Antioxidants (Basel). 2019 Jun 29;8(7):. (PMID: 31261915)
Eur J Pharmacol. 2017 Oct 5;812:91-96. (PMID: 28690190)
Biomed Pharmacother. 2019 Jan;109:1586-1592. (PMID: 30551412)
Front Immunol. 2020 Jul 21;11:1714. (PMID: 32793244)
Curr Opin Biotechnol. 2020 Feb;61:153-159. (PMID: 31954357)
J Biomol Struct Dyn. 2021 Oct;39(16):6306-6316. (PMID: 32698689)
Braz J Med Biol Res. 2019;52(7):e8092. (PMID: 31241712)
Virusdisease. 2020 Jun;31(2):179-193. (PMID: 32656311)
Molecules. 2020 Sep 01;25(17):. (PMID: 32882868)
Future Oncol. 2020 Sep;16(27):2029-2033. (PMID: 32658591)
Biomolecules. 2018 Jul 23;8(3):. (PMID: 30041464)
J Cancer Res Clin Oncol. 2020 Dec;146(12):3079-3096. (PMID: 32902794)
Nutrients. 2019 Jan 22;11(2):. (PMID: 30678156)
Front Immunol. 2019 Jan 31;10:51. (PMID: 30766532)
JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524)
Biochem Biophys Res Commun. 2018 Sep 3;503(1):21-25. (PMID: 29698678)
Drug Dev Res. 2021 Feb;82(1):86-96. (PMID: 32770567)
Endocr Rev. 2020 Jun 1;41(3):. (PMID: 32294179)
Chin Med. 2020 Jun 12;15:62. (PMID: 32536965)
Int J Biol Macromol. 2020 Dec 1;164:1693-1703. (PMID: 32745548)
Nat Prod Res. 2014;28(20):1772-6. (PMID: 24995563)
Pharmacogn Rev. 2012 Jan;6(11):1-5. (PMID: 22654398)
Crit Rev Food Sci Nutr. 2018;58(17):2908-2924. (PMID: 28682647)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Molecules. 2020 Jun 11;25(11):. (PMID: 32545268)
J Med Food. 2021 Jun;24(6):563-568. (PMID: 32816615)
Molecules. 2020 Feb 10;25(3):. (PMID: 32050623)
J Ethnopharmacol. 2018 Mar 25;214:47-57. (PMID: 29217496)
Food Chem. 2020 Sep 15;324:126847. (PMID: 32344340)
Phytomedicine. 2020 Dec;79:153350. (PMID: 33002827)
Diabetes Res Clin Pract. 2020 May;163:108162. (PMID: 32335097)
Cytokine. 2020 Sep;133:155151. (PMID: 32544563)
Cytokine Growth Factor Rev. 2020 Aug;54:62-75. (PMID: 32513566)
Food Funct. 2019 Feb 20;10(2):592-601. (PMID: 30672917)
Cancers (Basel). 2020 Jun 08;12(6):. (PMID: 32521759)
Molecules. 2020 Jan 22;25(3):. (PMID: 31979178)
Clin Immunol. 2020 May;214:108393. (PMID: 32222466)
Biomed Res Int. 2020 Feb 11;2020:5370759. (PMID: 32104696)
Med Hypotheses. 2020 Oct;143:110111. (PMID: 32721805)
Molecules. 2020 Feb 24;25(4):. (PMID: 32102475)
Curr Med Chem. 2019;26(37):6786-6796. (PMID: 30417769)
Contributed Indexing:: Keywords: Anti-inflammatory effects; COVID-19; Cytokine storm; Flavonoids; Immunomodulation; Inflammation; Phytochemicals; SARS-CoV-2
Substance Nomenclature:: 0 (Anti-Inflammatory Agents)
0 (Flavonoids)
Entry Date(s):: Date Created: 20210304 Date Completed: 20210426 Latest Revision: 20221207
Update Code:: 20240105
PubMed Central ID:: PMC7906511
DOI:: 10.1016/j.biopha.2021.111430
PMID:: 33662680
: Czasopismo naukowe

Full Text Finder

The disease severity of COVID-19, especially in the elderly and patients with co-morbidities, is characterized by hypercytokinemia, an exaggerated immune response associated with an uncontrolled and excessive release of proinflammatory cytokine mediators (cytokine storm). Flavonoids, important secondary metabolites of plants, have long been studied as therapeutic interventions in inflammatory diseases due to their cytokine-modulatory effects. In this review, we discuss the potential role of flavonoids in the modulation of signaling pathways that are crucial for COVID-19 disease, particularly those related to inflammation and immunity. The immunomodulatory ability of flavonoids, carried out by the regulation of inflammatory mediators, the inhibition of endothelial activation, NLRP3 inflammasome, toll-like receptors (TLRs) or bromodomain containing protein 4 (BRD4), and the activation of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2), might be beneficial in regulating the cytokine storm during SARS-CoV-2 infection. Moreover, the ability of flavonoids to inhibit dipeptidyl peptidase 4 (DPP4), neutralize 3-chymotrypsin-like protease (3CL pro ) or to affect gut microbiota to maintain immune response, and the dual action of angiotensin-converting enzyme 2 (ACE-2) may potentially also be applied to the exaggerated inflammatory responses induced by SARS-CoV-2. Based on the previously proven effects of flavonoids in other diseases or on the basis of newly published studies associated with COVID-19 (bioinformatics, molecular docking), it is reasonable to assume positive effects of flavonoids on inflammatory changes associated with COVID-19. This review highlights the current state of knowledge of the utility of flavonoids in the management of COVID-19 and also points to the multiple biological effects of flavonoids on signaling pathways associated with the inflammation processes that are deregulated in the pathology induced by SARS-CoV-2. The identification of agents, including naturally occurring substances such as flavonoids, represents great approach potentially utilizable in the management of COVID-19. Although not clinically investigated yet, the applicability of flavonoids against COVID-19 could be a promising strategy due to a broad spectrum of their biological activities.
(Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)

Informacja